beta-alanine has been researched along with Fuch's Endothelial Dystrophy in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-nine subjects with symptomatic Fuchs dystrophy were enrolled and randomized to use netarsudil or placebo eye drops once daily for 3 months." | 3.01 | Randomized, Double-Masked, Pilot Study of Netarsudil 0.02% Ophthalmic Solution for Treatment of Corneal Edema in Fuchs Dystrophy. ( Price, FW; Price, MO, 2021) |
| "Twenty eyes from 10 patients with Fuchs endothelial corneal dystrophy had DWEK with cataract surgery." | 1.62 | Pilot Study of Corneal Clearance With the Use of a Rho-Kinase Inhibitor After Descemetorhexis Without Endothelial Keratoplasty for Fuchs Endothelial Corneal Dystrophy. ( Davies, E; Jurkunas, U; Pineda, R, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kinoshita, S | 1 |
| Colby, KA | 1 |
| Kruse, FE | 1 |
| Syed, ZA | 1 |
| Rapuano, CJ | 1 |
| Price, MO | 1 |
| Price, FW | 1 |
| Davies, E | 1 |
| Jurkunas, U | 1 |
| Pineda, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Randomized Study to Determine Whether Use of Rhopressa™ Can Ameliorate Corneal Edema Associated With Fuchs Dystrophy[NCT04051463] | Phase 2/Phase 3 | 29 participants (Actual) | Interventional | 2019-08-05 | Completed | ||
| Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Primary Rhegmatogenous Detachments and Retinal Detachment Due to Proliferative Vitreoretinopathy or Open-Globe Injury: A Phase I/II Clinical Trial[NCT06033703] | Phase 1/Phase 2 | 48 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Central corneal thickness at 1 month after randomization minus central corneal thickness at baseline (NCT04051463)
Timeframe: 1 month
| Intervention | microns (Mean) |
|---|---|
| Netarsudil | -23 |
| Placebo | -2 |
Change in CDVA (lines read on the eye chart at 3 months minus lines read at baseline) (NCT04051463)
Timeframe: 3 months
| Intervention | lines on the eye chart (Mean) |
|---|---|
| Netarsudil | 1.9 |
| Placebo | 0.3 |
1 review available for beta-alanine and Fuch's Endothelial Dystrophy
| Article | Year |
|---|---|
Rho kinase (ROCK) inhibitors in the management of corneal endothelial disease.
Topics: Benzoates; beta-Alanine; Fuchs' Endothelial Dystrophy; Humans; Isoquinolines; Protein Kinase Inhibit | 2021 |
1 trial available for beta-alanine and Fuch's Endothelial Dystrophy
| Article | Year |
|---|---|
Randomized, Double-Masked, Pilot Study of Netarsudil 0.02% Ophthalmic Solution for Treatment of Corneal Edema in Fuchs Dystrophy.
Topics: Administration, Ophthalmic; Aged; Benzoates; beta-Alanine; Corneal Edema; Corneal Pachymetry; Double | 2021 |
2 other studies available for beta-alanine and Fuch's Endothelial Dystrophy
| Article | Year |
|---|---|
A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Ophthalmic; Benzoates; beta-Alanine; | 2021 |
Pilot Study of Corneal Clearance With the Use of a Rho-Kinase Inhibitor After Descemetorhexis Without Endothelial Keratoplasty for Fuchs Endothelial Corneal Dystrophy.
Topics: Administration, Ophthalmic; Aged; Aged, 80 and over; Benzoates; beta-Alanine; Cornea; Corneal Pachym | 2021 |